Novo Nordisk follows Lilly into DTC obesity drug market
Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 agonist weight-loss drug Wegovy, cutting the drug's price in half to $499 per month for those paying out-of-pocket.
Rivaling Eli Lilly’s (NYSE:LLY) direct-to-consumer platform LillyDirect, which made its market debut last year, Novo Nordisk ...
One of the few drug developers based in Worcester is leaving Wormtown for Waltham. Also, Novo Nordisk and Eli Lilly have ...
After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...
Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...
The weight-loss drug can cost patients more than $1,000 a month if they do not have health insurance coverage.
Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...
While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...
Zacks Investment Research on MSN17h
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback